A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage
Comparison of two combination chemotherapies in the treatment of patients with SLCL
The combination chemotherapies for this study are Carboplatin plus Irinotecan versus
Carboplatin plus Etoposide.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary Endpoint:
Ulrich Keilholz, MD
Principal Investigator
Charité Campus Benjamin Franklin University Clinic
Germany: Federal Institute for Drugs and Medical Devices
Haema CBF SCLC UK/AS 01
NCT00168896
October 2001
December 2006
Name | Location |
---|